Sign in
RENB Stock Price, Chart, Stats & News
Lunai Bioworks Inc.
Save
32.92M
Market cap
–
Current P/E
–
Forward P/E
RENB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 33.43% |
Operating margin | -70600.05% |
Pretax margin | -65059.63% |
Net margin | -65059.63% |
Effective tax rate | – |
ROA | -1882.91% |
ROE | -1241.35% |
D/E | -0.20x |
Interest coverage ratio | -1026.22x |
RENB valuation
P/E | – |
P/S | 170.61x |
P/B | -2.46x |
P/CF | 0.00x |
P/FCF | 0.00x |
P/OCF | 0.00x |
PEG | -0.01x |
EV multiple | -0.23x |
About
Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
Similar securities
Based on sector and market capitalization
Report issue